JP2008074862A5 - - Google Patents

Download PDF

Info

Publication number
JP2008074862A5
JP2008074862A5 JP2007279663A JP2007279663A JP2008074862A5 JP 2008074862 A5 JP2008074862 A5 JP 2008074862A5 JP 2007279663 A JP2007279663 A JP 2007279663A JP 2007279663 A JP2007279663 A JP 2007279663A JP 2008074862 A5 JP2008074862 A5 JP 2008074862A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007279663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008074862A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2008074862A publication Critical patent/JP2008074862A/ja
Publication of JP2008074862A5 publication Critical patent/JP2008074862A5/ja
Withdrawn legal-status Critical Current

Links

JP2007279663A 2001-03-29 2007-10-26 Aidsの処置に有用なccr5アンタゴニスト Withdrawn JP2008074862A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002577819A Division JP4248251B2 (ja) 2001-03-29 2002-03-27 Aidsの処置に有用なccr5アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2008074862A JP2008074862A (ja) 2008-04-03
JP2008074862A5 true JP2008074862A5 (enExample) 2009-01-15

Family

ID=23070981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002577819A Expired - Fee Related JP4248251B2 (ja) 2001-03-29 2002-03-27 Aidsの処置に有用なccr5アンタゴニスト
JP2007279663A Withdrawn JP2008074862A (ja) 2001-03-29 2007-10-26 Aidsの処置に有用なccr5アンタゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002577819A Expired - Fee Related JP4248251B2 (ja) 2001-03-29 2002-03-27 Aidsの処置に有用なccr5アンタゴニスト

Country Status (29)

Country Link
US (5) US6720325B2 (enExample)
EP (2) EP1373256B1 (enExample)
JP (2) JP4248251B2 (enExample)
KR (1) KR100613528B1 (enExample)
CN (1) CN100519554C (enExample)
AR (1) AR033452A1 (enExample)
AT (2) ATE466009T1 (enExample)
AU (1) AU2002255947B8 (enExample)
BR (1) BR0208398A (enExample)
CA (1) CA2442227C (enExample)
CZ (1) CZ20032636A3 (enExample)
DE (2) DE60204951T2 (enExample)
DK (1) DK1373256T3 (enExample)
ES (2) ES2342942T3 (enExample)
HU (1) HUP0400349A3 (enExample)
IL (1) IL157551A0 (enExample)
MX (1) MXPA03008853A (enExample)
MY (1) MY128609A (enExample)
NO (1) NO326349B1 (enExample)
NZ (1) NZ527768A (enExample)
PE (1) PE20020996A1 (enExample)
PL (1) PL364560A1 (enExample)
PT (1) PT1373256E (enExample)
RU (1) RU2316553C2 (enExample)
SI (1) SI1373256T1 (enExample)
SK (1) SK287521B6 (enExample)
TW (1) TWI237638B (enExample)
WO (1) WO2002079194A1 (enExample)
ZA (1) ZA200307474B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342942T3 (es) * 2001-03-29 2010-07-19 Schering Corporation Antagonistas de ccr5 utiles para el tratamiento del sida.
DK1404667T3 (da) 2001-07-02 2006-07-10 Astrazeneca Ab Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
DE60324014D1 (de) * 2002-12-13 2008-11-20 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
CA2544377A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
ES2324224T3 (es) * 2004-02-05 2009-08-03 Schering Corporation Derivados de piperidina que se pueden utilizar como antagonistas ccr3.
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
US7678798B2 (en) 2004-04-13 2010-03-16 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
PE20060598A1 (es) * 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008526862A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション ピペラジン化合物の薬学的な塩の調製
JP2008526863A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション Cc5r受容体アンタゴニストの合成
AU2006216731A1 (en) * 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
JP4822367B2 (ja) * 2005-02-23 2011-11-24 シェーリング コーポレイション ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
JP2010513521A (ja) * 2006-12-22 2010-04-30 シェーリング コーポレイション 4−置換1−シクロプロパン−スルホニル−ピペリジニル化合物を利用する、ccr−5レセプターアンタゴニストを調製するためのプロセス
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2182993T3 (es) 1995-06-07 2003-03-16 Kimberly Clark Co Inhibicion de exoproteinas en articulos absorbentes.
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
EP1175402B1 (en) 1999-05-04 2005-07-20 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
CZ20013940A3 (cs) * 1999-05-04 2002-04-17 Schering Corporation Piperazinové deriváty uľitečné jako CCR5 antagonisté
ES2342942T3 (es) * 2001-03-29 2010-07-19 Schering Corporation Antagonistas de ccr5 utiles para el tratamiento del sida.

Similar Documents

Publication Publication Date Title
JP2008074862A5 (enExample)
DE60021370C5 (de) Piperazinderivate verwendbar als ccr5 antagonisten
RU2001132632A (ru) Производные пиперазина, применимые в качестве антагонистов CCR5
JP2013505917A5 (enExample)
JP2007501859A5 (enExample)
RU2003131879A (ru) Антагонисты ccr5, полезные для лечения спид
JP2009534404A5 (enExample)
JP2008525417A5 (enExample)
JP2015501833A5 (enExample)
JP2006501292A5 (enExample)
JP2009545611A5 (enExample)
JP2011522866A5 (enExample)
JP2008133278A5 (enExample)
JP2014530240A5 (enExample)
JP2012512891A5 (enExample)
JP2006523193A5 (enExample)
JP2001526269A5 (enExample)
JP2012021003A5 (enExample)
JP2013523803A5 (enExample)
JP2013523802A5 (enExample)
JP2007523151A5 (enExample)
JP2001526222A5 (enExample)
JP2007531740A5 (enExample)
JP2012522729A5 (enExample)
RS53638B1 (en) CRYSTAL SOLVATES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLUCITOL WITH ALCOHOLS AS INHIBITORS OF SGLT2 FOR TREATMENT OF DIABETES